Litcius/Paper detail

Covid-19: EU countries spent over €220m stockpiling remdesivir despite lack of effectiveness, finds investigation

Lucien Hordijk, Priti Patnaik

2020BMJ92 citationsDOI

Abstract

The drug’s manufacturer was aware of the negative results of the Solidarity trial before the European Commission struck a procurement deal with it, finds an investigation by <b>Lucien Hordijk</b> and <b>Priti Patnaik</b>

Topics & Concepts

European commissionCoronavirus disease 2019 (COVID-19)Solidarity2019-20 coronavirus outbreakCommissionProcurementSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BusinessMedicineVirologyPolitical scienceEuropean unionInternational tradeLawMarketingPoliticsFinanceInfectious disease (medical specialty)DiseasePathologyOutbreakCOVID-19 Clinical Research StudiesCOVID-19 and healthcare impactsHealthcare Systems and Challenges
Covid-19: EU countries spent over €220m stockpiling remdesivir despite lack of effectiveness, finds investigation | Litcius